Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating whether expanding the use of finger-stick point-of-care testing for hepatitis C virus HCV can improve diagnosis and treatment rates among people at risk for HCV infection. This observational cohort study is conducted by the Kirby Institute and aims to support Australias goal of eliminating HCV by 2030 amid challenges such as declining treatment uptake and impacts from COVID-19. The study focuses on populations with risk factors, including those attending drug treatment clinics, needle and syringe programs, prisons, and other community services. Participants will attend a single visit where they will receive point-of-care HCV antibody testing, providing results within 1 to 20 minutes. If antibody positive, a further point-of-care HCV RNA test will be done to detect active infection. Those with previous HCV infection or treatment will be tested directly with the HCV RNA test. The study does not provide treatment, but participants testing positive for HCV RNA will be connected to standard care pathways for treatment initiation and further clinical evaluation. During the visit, participants will also complete a self-administered survey. Researchers will link survey responses to administrative data to assess long-term health outcomes and the impact of testing scale-up. The primary outcome is the proportion of participants who start HCV treatment within 12 weeks after testing positive. Secondary outcomes include treatment uptake timing, completion rates, cure rates, and cost-effectiveness of testing strategies. Participation involves only one visit, but follow-up data will be collected through linkage to health records over time.
Actively Recruiting
Heart failure and valvular heart disease are significant health concerns in rural and remote Australia, partly due to an aging population and higher rates of rheumatic heart disease in Aboriginal communities. These conditions often go undiagnosed until later stages, leading to avoidable hospital admissions and healthcare costs. This trial evaluates the use of artificial intelligence AI-based echocardiography to improve triage and management for patients with known or suspected heart disease in these areas. The study is a world-first randomized controlled trial aiming to detect early stages of heart failure and valvular disease, select appropriate management, and reduce hospital admissions while preserving quality of life. Participants will be randomly assigned to one of two groups. One group will receive AI-guided echocardiography performed by non-experts using a desktop echo machine with AI software at remote clinics images will be securely uploaded to the cloud for expert measurement and interpretation. The other group will receive standard echocardiography performed by sonographers at referral hospitals or visiting teams, which usually involves delays. The study involves up to 1200 individuals aged 45 or older with cardiovascular risk factors, recruited from multiple rural and remote locations and in partnership with Aboriginal communities. During the study, participants will undergo echocardiography according to their assigned group, with images analyzed centrally for diagnosis of cardiac dysfunction or valve disease over 12 months. Researchers will monitor management decisions and health outcomes related to heart failure and valvular disease. The primary outcome is the diagnosis of cardiac dysfunction or valve disease within a year. The study includes assessments through cloud-based image storage and expert review, aiming to improve access to this essential diagnostic test and support early intervention in rural and remote populations.